Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Date first appeared online 05/01/2020
DOI 10.1111/dom.13955
Authors Bain S.
Journal Name Diabetes, Obesity and Metabolism
Volume 22

Documents
  • 53094.pdf , Book, Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC).